EGFR positive

This case represents a rare report of surgical resection for breast cancer liver metastasis after CDK4/6 inhibitor-based therapy. It suggests that local treatment may be effective even in cases with suspected endocrine-resistant disease and provides practical insight into patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.

This study demonstrates that adjuvant abemaciclib+ET is being used at the labeled dosage in most Japanese patients. Furthermore, 2-year completion rates in patients with 2-year follow-up were comparable to the clinical trial data from monarchE (69%).

This study revealed the expression interplay and clinical significance of KIF2A and p53 in breast cancer. The identified association between KIF2A and p53 may provide insights for future research on their roles in breast cancer.

P=N/A, N=200, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Jun 2027

The majority of patients (72%) were treated in the first-line setting; 11 received ribociclib, 15 received palbociclib, and 3 received abemaciclib. Whether this translates into deferring disease progression requires randomized studies with larger treatment groups. To our knowledge, this study represents the first analysis evaluating 18F-FDG-PET/CT-guided SBRT in combination with CDK4/6 inhibitor-based therapy in patients with metastatic breast cancer.

However, the pressure re-elevated despite maximal topical antiglaucoma therapy (including a prostaglandin analog, beta-blocker, carbonic anhydrase inhibitor, alpha-2 agonist, and Rho-kinase inhibitor) and oral acetazolamide...This case underscores the diagnostic utility of anterior chamber paracentesis as a less invasive yet reliable alternative to iris biopsy in carefully selected patients. It also highlights the clinical course and therapeutic challenges in managing anterior segment metastasis from epithelial tumors such as lung cancer.

These bidirectional changes indicate a metabolic coupling between tumor and circulation, driven by differential utilization and excretion processes during T-DM1 response. Collectively, our findings demonstrate that T-DM1 elicits coordinated local and systemic metabolic reprogramming, providing mechanistic insights into its antitumor activity and the metabolic coupling between tumor and circulation.

In conclusion, integrating intratumoral, inner peritumoral, and outer peritumoral radiomic features (Rad All model) may provide more reliable predictive performance for postoperative recurrence in HER2-positive breast cancer compared with single-region radiomic models. The combined nomogram incorporating Rad All and clinical risk factors further improves predictive efficacy and may serve as a supplementary tool for clinical decision-making. SHAP analysis enhances model interpretability by identifying key predictive features. However, given the lack of independent external validation, the generalizability of our models needs to be further verified in future prospective multi-center studies.

Elevated levels of phosphoglycerate, pyruvate, ribose 5 phosphate, glutamate, and 2 oxoglutarate suggested enhanced proliferative and biosynthetic metabolism, while enrichment of long chain fatty acids in Luminal A samples indicated subtype specific lipid metabolic remodeling. These findings demonstrate the feasibility of combining MagLev derived plasma organization with metabolomics analysis to generate disease specific metabolomic fingerprints and establish a foundation for future large scale validation studies.

This case demonstrates the effectiveness of first-generation TKIs in treating metastatic EGFR-positive NSCLC, particularly in countries that cannot afford recent targeted therapies. In addition, it describes a rare adverse effect that was well tolerated and managed successfully.

This article reviews findings on the interplay between EGFR, the tumor microenvironment, and ICIs, as well as recent advances in post-EGFR-TKI resistance treatment strategies. By doing so, this review aims to provide insights for research and clinical management of EGFR-TKI-resistant NSCLC.

Treatment of HER2+ mBC with and without BMs in Saudi Arabia largely aligned with international recommendations identified in our literature analysis, although access to lapatinib, tucatinib and neratinib can be limited and may lead to use of alternative regimens. The tucatinib-combination may be considered the standard of care for adult patients with HER2+ locally advanced or mBC who have received at least two prior anti-HER2+ treatment regimens, including patients with BMs. Ensuring access to innovative HER2+ mBC therapies across Saudi Arabia is crucial to supporting best practice.